Why the study?
What is the pharmacokinetic variability of doxorubicin in children treated for acute lymphoblastic leukemia?
Population
112 pediatric patients treated for acute lymphoblastic leukemia undergoing induction therapy.
Design
Cohort
Follow-up
23 hours after start of infusion
Authors
Loading...
High doxorubicin exposure variability in pediatric ALL may influence toxicity; leaves open whether age-adjusted dosing warrants prospective evaluation.
What is the pharmacokinetic variability of doxorubicin in children treated for acute lymphoblastic leukemia?
Doxorubicin pharmacokinetics are highly variable in children with ALL despite BSA-based dosing, with age and tumor burden influencing plasma concentrations.
Frost et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: